AIToday
Top Companies' AI MovesTop Companies AIPublished: Jun 13, 2026, 06:30 JST

GE Vernova lands 100 MW India wind contract and reports strong data-center-driven orders, reinforcing its grid infrastructure growth story amid AI power demand.

3 Key Points

  1. What happened

    In early June 2026, GE Vernova launched a 3.8 MW onshore wind turbine and secured a 100 MW order from Powerica for India's Botad Wind Farm, with deliveries scheduled to begin in Q4 2026. In Q1 2026, the company reported US$9,339 million(約1.5兆円) in quarterly revenue, a US$163 billion(約26兆円) backlog, and US$2.4 billion(約3800億円) of data center related Electrification orders booked in a single quarter.

  2. Why it matters

    The new India wind contract and continued stream of Electrification orders tied to AI data center power needs validate GE Vernova's investment thesis—that there is a sustained runway for grid and electrification projects. However, the company still faces execution risks in large offshore wind projects and tariff pressures in its Wind business, so the order wins alone do not eliminate those concerns.

  3. What to watch

    GE Vernova's narrative projects US$57.9 billion(約9.3兆円) in revenue and US$8.6 billion(約1.4兆円) in earnings by 2029, requiring 15.0% yearly revenue growth. The most optimistic analysts see US$68 billion(約11兆円) revenue and US$12.6 billion(約2兆円) earnings by 2029, assuming execution and legacy wind liabilities do not worsen.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, in your inbox every morning.

Top Companies AIRead Original Article

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articleTakeda Pharmaceutical's oral immunology candidate Zasochtinib showed statistical superiority over a competing therapy in a Phase 3 trial for moderate-to-severe plaque psoriasis, bolstering the company's late-stage pipeline story, though the company simultaneously scaled back a planned equity offering.